June 26, 2019
Zealand Pharma kicks off dosing patients in testing SBS potential treatment
Zealand Pharma has dosed the first out of 64 healthy patients, in a Phase 1 clinical test of ZP7570 as a potential first-in-class next generation treatment of short bowel syndrome (SBS).